Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
721
datasets available to search
ShareScore release 0.9.0
Dataset results
721 results for “Systemic lupus erythematosus”
Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
ClinicalTrials.gov study NCT02794285. IPD Sharing: Not stated. Countries: 24. Publications: 3.
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
ClinicalTrials.gov study NCT01972568. IPD Sharing: Not stated. Countries: 18. Publications: 3.
Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis
ClinicalTrials.gov study NCT03334851. IPD Sharing: NO. Countries: 1. Publications: 1.
Acthar Gel for Active Systemic Lupus Erythematosus (SLE)
ClinicalTrials.gov study NCT02953821. IPD Sharing: NO. Countries: 5. Publications: 4.
Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone
ClinicalTrials.gov study NCT00119678. IPD Sharing: Not stated. Countries: 15. Publications: 3.
A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus
ClinicalTrials.gov study NCT02437890. IPD Sharing: Not stated. Countries: 17. Publications: 1.
Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)
ClinicalTrials.gov study NCT00732940. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)
ClinicalTrials.gov study NCT00071487. IPD Sharing: Not stated. Countries: 2. Publications: 12.
Vitamin D3 in Systemic Lupus Erythematosus
ClinicalTrials.gov study NCT00710021. IPD Sharing: YES. Countries: 1. Publications: 6.
Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus
ClinicalTrials.gov study NCT02472795. IPD Sharing: NO. Countries: 6. Publications: 1.
Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)
ClinicalTrials.gov study NCT02847598. IPD Sharing: Not stated. Countries: 12. Publications: 5.
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
ClinicalTrials.gov study NCT00137969. IPD Sharing: Not stated. Countries: 2. Publications: 1.
A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus
ClinicalTrials.gov study NCT02349061. IPD Sharing: Not stated. Countries: 9. Publications: 5.
Data from: First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)–Pan-American League of Associations of Rheumatology (PANLAR)
Systemic lupus erythematosus (SLE), a complex and heterogeneous autoimmune disease, represents a significant challenge for both diagnosis and treatment. Patients with SLE in Latin America face special problems that should be considered when therapeutic guidelines are developed. The objective of the study is to develop clinical practice guidelines for Latin American patients with lupus. Two independent teams (rheumatologists with experience in lupus management and methodologists) had an initial meeting in Panama City, Panama, in April 2016. They selected a list of questions for the clinical problems most commonly seen in Latin American patients with SLE. These were addressed with the best available evidence and summarised in a standardised format following the Grading of Recommendations Assessment, Development and Evaluation approach. All preliminary findings were discussed in a second face-to-face meeting in Washington, DC, in November 2016. As a result, nine organ/system sections are presented with the main findings; an 'overarching' treatment approach was added. Special emphasis was made on regional implementation issues. Best pharmacologic options were examined for musculoskeletal, mucocutaneous, kidney, cardiac, pulmonary, neuropsychiatric, haematological manifestations and the antiphospholipid syndrome. The roles of main therapeutic options (ie, glucocorticoids, antimalarials, immunosuppressant agents, therapeutic plasma exchange, belimumab, rituximab, abatacept, low-dose aspirin and anticoagulants) were summarised in each section. In all cases, benefits and harms, certainty of the evidence, values and preferences, feasibility, acceptability and equity issues were considered to produce a recommendation with special focus on ethnic and socioeconomic aspects. Guidelines for Latin American patients with lupus have been developed and could be used in similar settings.
Treatment of Refractory Systemic Lupus Erythematosus by Allogeneic Mesenchymal Stem Cells Derived From the Umbilical Cord
ClinicalTrials.gov study NCT03562065. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Walk With Ease Program For Patients With Systemic Lupus Erythematosus
ClinicalTrials.gov study NCT02631005. IPD Sharing: NO. Countries: 1. Publications: 16.
Pilot Study of Cyclophosphamide in Patients With Life-Threatening Systemic Lupus Erythematosus or Antiphospholipid Antibody Syndrome
ClinicalTrials.gov study NCT00010400. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Serological and Urinary Biomarkers in Latin American Patients With Systemic Lupus Erythematosus: GLADEL 2.0 Cohort
ClinicalTrials.gov study NCT04534647. IPD Sharing: NO. Countries: 1. Publications: 0.
Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 (Litifilimab) in Healthy Volunteers and Participants With Systemic Lupus Erythematosus
ClinicalTrials.gov study NCT02106897. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Immune Ablation and Hematopoietic Stem Cell Support in Patients With Systemic Lupus Erythematosus: A Phase II Study
ClinicalTrials.gov study NCT00271934. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.